Pharmaceutical Companies Expanding mRNA Technology to Treat Influenza
March 23rd, 2022Via: Epoch Times:
Seqirus said it would begin clinical trials of its seasonal and pandemic flu vaccine candidates in the second half of 2022.
Pfizer, Moderna, and Sanofi began testing their mRNA flu vaccines in adults 18 and older in 2021, while Curevac announced last month it was conducting a small Phase 1 trial in Panama.
Moderna released interim data for the Phase 1 trial of its quadrivalent (four-strain) seasonal flu vaccine candidate, mRNA-1010 in December 2021, and announced that its two-dose vaccine produced robust antibody titers with “no significant safety concerns” observed, even at the lowest dose of 50 micrograms.
